Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies that inhibit tumor metabolism and signaling pathways. Founded in 2019 and taken public in 2026 via a reverse merger with Sensei Biotherapeutics, Faeth employs a data-driven approach to match tumor genotypes with specific treatment regimens. The company's scientific foundation is built on overcoming the limitations of single-node inhibitors, which often fail due to a tumor's ability to reroute its signaling. Faeth's lead clinical program, PIKTOR, is a proprietary, all-oral combination of two small molecule inhibitors, serabelisib and sapanisertib. PIKTOR is designed to simultaneously inhibit multiple nodes of the PI3K/AKT/mTOR (PAM) pathway—specifically PI3K-alpha and mTORC1/2—to achieve deeper pathway suppression and improved tolerability. The company is actively advancing PIKTOR through a Phase 2 clinical trial for second-line advanced endometrial cancer and a Phase 1b trial for HR+/HER2- advanced breast cancer. As a pre-revenue biotech firm, Faeth does not currently generate commercial product revenue and funds its operations through equity financing, including a $200 million private placement concurrent with its 2026 merger. The company is headquartered in Austin, Texas.
